ALX ONCOLOGY HOLDINGS INC
ALXONasdaq
$2.10
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +349.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$219.6M
Enterprise Value
$87.8M
P/E
—
P/S
—
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-35.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$88.9M
Free Cash Flow (TTM)
-$78.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-58.7%
ROIC
-368.7%
Debt / Equity
0.1
Net Cash
$131.8M
Return 1Y
+326.8%
Company profile
ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
- CEO
- Jaume Pons
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- alxoncology.com
Management & directors
- Pinto ShellySVP, FINANCE AND CAO
- Lettmann JasonCHIEF EXECUTIVE OFFICER
- Shantharam HarishChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ALXO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.17↓ -70.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $0.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.7M | -$83.6M | -$127.4M | -$170.3M | -$142.5M | -$104.0M |
| Net income | -$45.7M | -$83.5M | -$123.5M | -$160.8M | -$134.8M | -$101.7M |
| Diluted EPS | -$2.76 | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
| Operating cash flow | -$38.3M | -$68.1M | -$89.2M | -$130.4M | -$121.9M | -$84.1M |
| Free cash flow | -$38.3M | -$68.8M | -$90.7M | -$131.6M | -$122.4M | -$84.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3694.0% | — | — | — | — | — |
| Net margin | -3869.7% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$41.5M | -$32.6M | -$30.6M | -$31.8M | -$26.6M | -$22.5M | -$23.0M | -$19.0M |
| Net income | -$39.4M | -$30.7M | -$29.2M | -$30.8M | -$25.9M | -$22.1M | -$22.8M | -$17.9M |
| Diluted EPS | -$0.76 | -$0.58 | -$0.53 | -$0.58 | -$0.49 | -$0.41 | -$0.42 | -$0.17 |
| Operating cash flow | -$26.6M | -$25.4M | -$32.0M | -$24.7M | -$23.4M | -$17.1M | -$19.0M | -$18.6M |
| Free cash flow | -$26.7M | -$25.5M | -$32.1M | -$24.7M | -$23.5M | -$17.1M | -$19.0M | -$18.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 9, 2026
Jun 30, 2026
Jun 4, 2026
Jun 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 1,404 | $2.04 | $2,864.16 | filing |
| 2026-03-19 | Lettmann Jason· CHIEF EXECUTIVE OFFICER | Sale | 12,311 | $2.17 | $26,714.87 | filing |
| 2026-03-19 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 903 | $2.17 | $1,959.51 | filing |
| 2026-02-18 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 565 | $2.27 | $1,282.55 | filing |
| 2026-02-17 | Lettmann Jason· CHIEF EXECUTIVE OFFICER | Tax withholding | 2,201 | $2.27 | $4,996.27 | filing |
| 2026-02-02 | GOODMAN COREY S | Buy | 3,184,713 | $1.57 | $5.0M | filing |
| 2026-01-06 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 3,925 | $1.11 | $4,356.75 | filing |
| 2025-09-17 | Lettmann Jason· CHIEF EXECUTIVE OFFICER | Buy | 71,163 | $1.08 | $76,891.62 | filing |
| 2025-09-16 | Lettmann Jason· CHIEF EXECUTIVE OFFICER | Buy | 21,070 | $1.07 | $22,460.62 | filing |
| 2025-08-18 | Shantharam Harish· Chief Financial Officer | Buy | 75,000 | $0.78 | $58,402.50 | filing |
| 2025-08-15 | Lettmann Jason· CHIEF EXECUTIVE OFFICER | Sale | 2,382 | $0.64 | $1,525.43 | filing |
| 2025-08-15 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 611 | $0.64 | $391.28 | filing |
| 2025-07-07 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 2,011 | $0.45 | $905.15 | filing |
| 2025-06-30 | Pinto Shelly· SVP, FINANCE AND CAO | Sale | 1,532 | $0.43 | $658.76 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.